EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy

On September 23, 2026, AstraZeneca announced that asthma maintenance treatment, Trixeo, was approved in the European Union.¹ The European Commission approved Trixeo Aerosphere (budesonide/ glycopyrronium/ formoterol fumarate dihydrate, 320/28.8/10 mcg) for the maintenance treatment of asthma in patients aged 12 and older whose disease remains inadequately controlled on medium-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy. Trixeo is the first triple-combination therapy approved in the EU for asthma delivered in a single inhaler, extending a product line already approved for chronic obstructive pulmonary disease (COPD) in more than 90 countries.

Improvement in Lung Function

The decision was based on the recommendation from the European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use (CHMP),² and came after results from phase 3 KALOS and LOGOS trials, 2 replicate, randomized, double-blind studies spanning roughly 4300 patients over 24 to 52 weeks. Trixeo produced statistically significant lung-function improvements and a significant reduction in severe exacerbation rates compared with inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapy, including benefit in patients with no exacerbations in the prior year, with no new safety signals and onset within 5 minutes of the first dose.

“Today’s approval in asthma builds on Trixeo’s established role in improving outcomes in patients with COPD,” Ruud Dobber, executive vice president and president, BioPharmaceuticals Business Unit, AstraZeneca, said in a press release.¹ “This means we can now bring the benefits of a single-inhaler triple-combination therapy to people aged 12 years and older in Europe whose asthma remains uncontrolled on dual inhaled therapy.”

What This May Mean for Manufacturers

Trixeo is built on AstraZeneca's proprietary Aerosphere formulation, a pressurized metered-dose inhaler (pMDI) platform that suspends 3 active ingredients as porous microparticles for consistent co-delivery in a single actuation. Producing a fixed-dose triple therapy at commercial scale is markedly more demanding than a single- or dual-agent inhaler: it requires tightly controlled particle engineering, precise dose uniformity across 3 actives, specialized canister-filling lines, and rigorous in-use and stability testing across shelf life. With nearly 43 million people living with asthma in Europe and about 4 million new diagnoses annually, and roughly half of patients remaining uncontrolled on dual therapy, a new eligible population now enters the addressable market for this class, adding pressure on fill-finish capacity, valve and actuator component supply, and analytical testing throughput industry-wide.

The timing also intersects with the industry's shift away from high-global-warming-potential (GWP) propellants used in most pMDIs. AstraZeneca has already secured EU approval to reformulate Trixeo with a next-generation, near-zero-GWP propellant, and manufacturers across the respiratory space are racing to requalify formulations, canisters, and filling equipment ahead of tightening environmental rules in Europe and elsewhere.³ An asthma indication broadens the volume base over which that propellant transition must be executed, raising the stakes and opportunity for contract development and manufacturing organizations (CDMOs) and component suppliers with pMDI capability.

There are competitive and supply-chain implications, too. AstraZeneca's move deepens its lead in single-inhaler triple therapy for airways disease at a moment when generic-drug manufacturers are advancing copies of earlier-generation combination inhalers and competitors are developing biologics and small-molecule alternatives for respiratory disease, as PharmTech coverage of European biotechs reshaping respiratory disease has noted.⁴ It also lands amid AstraZeneca's broader manufacturing expansion, including a multibillion-dollar US investment program with new chronic-disease capacity in Virginia — a reminder that regulatory wins like this one tend to arrive alongside, and reinforce the case for, continued capital investment in dedicated inhaler lines.⁵

For contract manufacturers and component suppliers specifically, an asthma label expansion for an established pMDI product typically brings demand signals well before launch: higher forecasts for canisters, metering valves, and actuators; added stability and in-use testing lots for the new patient population; and often renegotiated long-term supply agreements to de-risk the larger volume base. Combined with the parallel push toward near-zero-GWP propellants, manufacturers evaluating device platforms or capacity investment in inhaled respiratory products now have a clearer signal that European regulators will expand triple-combination pMDI therapy beyond COPD into asthma, a potential precedent that formulation teams and CDMOs weighing new or expanded pMDI filling lines will likely watch closely.

References

1. Trixeo approved in the EU for the maintenance treatment of asthma. Press release. AstraZeneca. September 23, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/trixeo-approved-in-the-eu-for-the-maintenance-treatment-of-asthma.html

2. CHMP. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026. Press release. EMA. July 24, 2026. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026

3. EMA. First reformulation of an inhaled medicine with environmentally friendly gas propellant. Press Release. July 25, 2025. https://www.ema.europa.eu/en/news/first-reformulation-inhaled-medicine-environmentally-friendly-gas-propellant

4. Barton C. European biotechs reshaping respiratory disease. PharmTech.com. July 27, 2026. https://www.pharmtech.com/view/european-biotechs-reshaping-respiratory-disease

5. AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D. Press release. AstraZeneca. July 21, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html